Overview
In this poster, PathAI presented results of a controlled cross-over study evaluating pathologist workflows with and without TumorDetect, PathAI's AI-powered case prioritization algorithm, in the context of the AISight® Dx platform.
Key Takeaways
- Slides with suspected cancer were reviewed earlier when using a TumorDetect-assisted workflow, supporting TumorDetect's ability to expedite review of ground-truth malignant cases within a larger set of assigned cases.
- Pathologists demonstrated higher agreement with ground-truth diagnoses when using TumorDetect compared to working without it.
USCAP 2026